DigestRedComo funciona
Red
/
Empresas
Vi
No verificado

ViiV Healthcare

Sobre qué escribimos

FarmacéuticaIndustriaMedicina - VariosSaludVIH, SIDA y enfermedades autoinmunes

20 Comunicados de prensa

Ver todos los comunicados de prensa
25/02/2026
Industria
VIH, SIDA y enfermedades autoinmunes
Salud
Sanidad
Medicina - Varios
Ciencia
Farmacéutica
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
25/02/2026
Eventos
Ferias y Congresos
Industria
VIH, SIDA y enfermedades autoinmunes
Salud
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
18/02/2026
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Biotecnología
Sanidad
Farmacéutica
Salud
Industria
ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
17/02/2026
Eventos
Industria
Ciencia
Biotecnología
Farmacéutica
VIH, SIDA y enfermedades autoinmunes
Salud
Medicina - Varios
ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
17/10/2025
Biotecnología
Farmacéutica
VIH, SIDA y enfermedades autoinmunes
Sanidad
Salud
Higiene alimentaria
Medicina - Varios
Industria
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
15/10/2025
Sanidad
Gestión empresarial
Farmacéutica
Venta al público/Minorista
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Biotecnología
Ciencia
Asistencia a la infancia
Ir de compras
Salud
Industria
Análisis de Mercados
ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
09/10/2025
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Eventos
Ferias y Congresos
ViiV Healthcare showcases breadth of clinical and real-world evidence at EACS and IDWeek 2025
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
14/07/2025
VIH, SIDA y enfermedades autoinmunes
Farmacéutica
Salud
Análisis de Mercados
Industria
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
14/07/2025
VIH, SIDA y enfermedades autoinmunes
Farmacéutica
Salud
Análisis de Mercados
Industria
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
14/07/2025
VIH, SIDA y enfermedades autoinmunes
Salud
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
Industria
ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0